The Neurodevelopmental and Molecular Landscape of Medulloblastoma Subgroups: Current Targets and the Potential for Combined Therapies.
combination therapy
medulloblastoma subgroups
molecular pathways
neurodevelopmental origin
pediatric brain tumors
targeted therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Jul 2023
30 Jul 2023
Historique:
received:
26
06
2023
revised:
24
07
2023
accepted:
28
07
2023
medline:
12
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Medulloblastoma is the most common malignant pediatric brain tumor and is associated with significant morbidity and mortality in the pediatric population. Despite the use of multiple therapeutic approaches consisting of surgical resection, craniospinal irradiation, and multiagent chemotherapy, the prognosis of many patients with medulloblastoma remains dismal. Additionally, the high doses of radiation and the chemotherapeutic agents used are associated with significant short- and long-term complications and adverse effects, most notably neurocognitive delay. Hence, there is an urgent need for the development and clinical integration of targeted treatment regimens with greater efficacy and superior safety profiles. Since the adoption of the molecular-based classification of medulloblastoma into wingless (WNT) activated, sonic hedgehog (SHH) activated, group 3, and group 4, research efforts have been directed towards unraveling the genetic, epigenetic, transcriptomic, and proteomic profiles of each subtype. This review aims to delineate the progress that has been made in characterizing the neurodevelopmental and molecular features of each medulloblastoma subtype. It further delves into the implications that these characteristics have on the development of subgroup-specific targeted therapeutic agents. Furthermore, it highlights potential future avenues for combining multiple agents or strategies in order to obtain augmented effects and evade the development of treatment resistance in tumors.
Identifiants
pubmed: 37568705
pii: cancers15153889
doi: 10.3390/cancers15153889
pmc: PMC10417410
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Biochem Cell Biol. 2022 Apr;100(2):142-151
pubmed: 34990285
Neuro Oncol. 2022 Mar 12;24(3):414-426
pubmed: 34477871
Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13432-7
pubmed: 20624968
Acta Neuropathol. 2013 Mar;125(3):373-84
pubmed: 23184418
Nature. 2019 Aug;572(7767):67-73
pubmed: 31043743
Radiother Oncol. 2011 Oct;101(1):203-8
pubmed: 21704399
Cancer Cell. 2017 Jun 12;31(6):737-754.e6
pubmed: 28609654
Mol Cancer Ther. 2015 Jan;14(1):3-13
pubmed: 25376612
J Neurooncol. 2016 Sep;129(3):453-460
pubmed: 27377654
Childs Nerv Syst. 2015 Sep;31(9):1433-45
pubmed: 26188774
Nature. 2022 Sep;609(7929):1012-1020
pubmed: 36131015
Nat Commun. 2020 Jul 20;11(1):3627
pubmed: 32686664
Acta Neuropathol. 2016 Jun;131(6):821-31
pubmed: 27040285
J Exp Clin Cancer Res. 2022 Nov 11;41(1):321
pubmed: 36357906
Oncotarget. 2015 Aug 28;6(25):21718-29
pubmed: 26061748
Cancer Cell. 2012 Feb 14;21(2):155-67
pubmed: 22340590
N Engl J Med. 2022 May 19;386(20):1922-1931
pubmed: 35584157
ChemMedChem. 2013 Aug;8(8):1261-5
pubmed: 23821351
J Biomed Nanotechnol. 2016 Jun;12(6):1297-302
pubmed: 27319222
Biochem Biophys Res Commun. 2014 Aug 8;450(4):1600-5
pubmed: 25026552
Cancer Res. 2017 Mar 15;77(6):1416-1426
pubmed: 28031228
Cerebellum. 2018 Feb;17(1):28-36
pubmed: 29178021
Acta Neuropathol Commun. 2020 May 14;8(1):70
pubmed: 32410663
Mol Cancer Ther. 2023 Jan 3;22(1):37-51
pubmed: 36318650
J Clin Oncol. 2016 Dec;34(34):4161-4170
pubmed: 27507873
Cancer Biol Ther. 2019;20(11):1398-1402
pubmed: 31423907
Nat Med. 2014 Jul;20(7):732-40
pubmed: 24973920
ACS Med Chem Lett. 2010 Mar 16;1(3):130-4
pubmed: 24900187
Nat Med. 2020 May;26(5):720-731
pubmed: 32341580
Mol Cancer Ther. 2020 Jun;19(6):1351-1362
pubmed: 32371591
Sci Rep. 2020 Apr 22;10(1):6836
pubmed: 32321992
Nat Rev Dis Primers. 2019 Feb 14;5(1):11
pubmed: 30765705
J Clin Oncol. 2010 Aug 1;28(22):3623-9
pubmed: 20606092
Neuro Oncol. 2007 Apr;9(2):135-44
pubmed: 17329407
Oncogene. 2008 Apr 7;27(16):2276-88
pubmed: 18391970
Nat Genet. 2019 Dec;51(12):1702-1713
pubmed: 31768071
J Neurooncol. 2010 May;97(3):353-64
pubmed: 19865800
J Pediatr Hematol Oncol. 2019 May;41(4):e235-e241
pubmed: 30681550
Clin Cancer Res. 2021 May 1;27(9):2442-2451
pubmed: 33547201
Oncotarget. 2018 Mar 30;9(24):16619-16633
pubmed: 29682173
Prostate Cancer. 2013;2013:418340
pubmed: 24396604
Childs Nerv Syst. 2015 Aug;31(8):1283-9
pubmed: 25930724
Cancer Cell. 2010 Apr 13;17(4):388-99
pubmed: 20385363
Oncol Res. 2021 Sep 7;28(7):791-800
pubmed: 33858561
Oncol Rep. 2019 Jan;41(1):178-190
pubmed: 30320358
N Engl J Med. 2012 Jun 7;366(23):2171-9
pubmed: 22670903
Cancer Metastasis Rev. 2020 Mar;39(1):211-233
pubmed: 31970590
Neuron. 2005 Oct 6;48(1):31-43
pubmed: 16202707
Cancer Discov. 2017 Nov;7(11):1320-1335
pubmed: 28790030
J Clin Oncol. 2021 Aug 20;39(24):2685-2697
pubmed: 34110925
Nature. 2009 Oct 1;461(7264):614-20
pubmed: 19759537
Am J Surg Pathol. 2017 Jun;41(6):781-787
pubmed: 28338501
Bioorg Med Chem. 2020 Mar 15;28(6):115354
pubmed: 32063403
Mol Med Rep. 2017 Apr;15(4):1909-1915
pubmed: 28260041
J Clin Oncol. 2008 Feb 20;26(6):919-24
pubmed: 18281665
Childs Nerv Syst. 2009 Jul;25(7):787-93
pubmed: 19082611
Cancers (Basel). 2022 Oct 19;14(20):
pubmed: 36291912
J Clin Oncol. 2010 Jul 1;28(19):3182-90
pubmed: 20516456
Sci Transl Med. 2010 Sep 29;2(51):51ra70
pubmed: 20881279
Int J Cancer. 2012 Oct 15;131(8):1800-9
pubmed: 22287205
Cancer Cell. 2016 Mar 14;29(3):311-323
pubmed: 26977882
J Clin Oncol. 2001 Aug 1;19(15):3470-6
pubmed: 11481352
Front Oncol. 2019 May 14;9:391
pubmed: 31139573
Eur J Med Chem. 2017 Dec 15;142:506-522
pubmed: 29107427
J Neurooncol. 2015 Jan;121(1):217-24
pubmed: 25407389
Hum Mol Genet. 2021 Nov 30;30(24):2416-2428
pubmed: 34274968
J Neurosurg Pediatr. 2021 Feb 05;27(4):482-488
pubmed: 33545678
Cancer Cell. 2014 Mar 17;25(3):393-405
pubmed: 24651015
Clin Cancer Res. 2016 Aug 1;22(15):3903-14
pubmed: 27012813
Mol Ther Nucleic Acids. 2018 Sep 7;12:490-503
pubmed: 30195786
Clin Cancer Res. 2016 Feb 1;22(3):582-95
pubmed: 26405194
Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12986-12995
pubmed: 31182587
Neuro Oncol. 2021 Apr 12;23(4):572-585
pubmed: 33844835
J Cancer Res Clin Oncol. 2016 Dec;142(12):2469-2478
pubmed: 27601167
Front Oncol. 2021 Jun 08;11:660892
pubmed: 34168987
Cancer Cell. 2019 Sep 16;36(3):302-318.e7
pubmed: 31474569
Science. 2019 Oct 25;366(6464):454-460
pubmed: 31624095
Acta Neuropathol Commun. 2021 Dec 18;9(1):195
pubmed: 34922631
J Clin Oncol. 2014 Mar 20;32(9):886-96
pubmed: 24493713
Acta Biomed. 2020 Jun 30;91(7-S):79-100
pubmed: 32608377
Pediatr Blood Cancer. 2011 Apr;56(4):532-43
pubmed: 21298737
PLoS One. 2015 Apr 02;10(4):e0124149
pubmed: 25835728
Front Neural Circuits. 2021 Jan 15;14:611841
pubmed: 33519389
Nature. 2017 Jul 19;547(7663):311-317
pubmed: 28726821
Oncotarget. 2015 Nov 17;6(36):38827-39
pubmed: 26420814
Neuro Oncol. 2017 Oct 19;19(11):1542-1552
pubmed: 28605510
Expert Opin Ther Targets. 2020 Nov;24(11):1159-1181
pubmed: 32990091
Oncogene. 2018 May;37(21):2850-2862
pubmed: 29511348
Oncogene. 2021 Jan;40(2):396-407
pubmed: 33159168
Clin Cancer Res. 2014 Apr 1;20(7):1900-9
pubmed: 24523439
Neuro Oncol. 2023 Feb 14;25(2):234-247
pubmed: 36197833
Biochem Biophys Res Commun. 2011 Jul 22;411(1):208-12
pubmed: 21726539
Med Res Rev. 2018 May;38(3):870-913
pubmed: 29315702
Nat Commun. 2018 Oct 8;9(1):4121
pubmed: 30297829
Oncotarget. 2014 May 15;5(9):2355-71
pubmed: 24796395
PLoS One. 2021 Nov 3;16(11):e0251957
pubmed: 34731160
Nat Rev Drug Discov. 2014 Jul;13(7):513-32
pubmed: 24981364
Cell Rep. 2022 Aug 2;40(5):111162
pubmed: 35926460
Nature. 2012 Aug 2;488(7409):43-8
pubmed: 22722829
Nat Rev Cancer. 2020 Jan;20(1):42-56
pubmed: 31819232
Cancer Res. 2009 Apr 15;69(8):3249-55
pubmed: 19351822
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Cerebellum. 2016 Dec;15(6):789-828
pubmed: 26439486
Eur J Med Chem. 2021 Apr 5;215:113268
pubmed: 33636537
Int J Mol Sci. 2023 Jan 10;24(2):
pubmed: 36674870
J Clin Oncol. 2005 Nov 1;23(31):7951-7
pubmed: 16258095
Cancer Res. 2017 Oct 15;77(20):5628-5638
pubmed: 28904063
Breast Cancer Res Treat. 2017 Nov;166(1):95-107
pubmed: 28730338
Ann Oncol. 2015 Jul;26(7):1314-24
pubmed: 25605740
Am J Pathol. 2001 Apr;158(4):1525-32
pubmed: 11290570
Clin Cancer Res. 2017 Oct 1;23(19):5802-5813
pubmed: 28637687
J Clin Oncol. 2010 Jun 20;28(18):3061-8
pubmed: 20479398
Mol Biosyst. 2015 Jul;11(7):1946-54
pubmed: 25924008
Annu Rev Neurosci. 2018 Jul 8;41:207-232
pubmed: 29641939
Neoplasia. 2023 Jan;35:100861
pubmed: 36516489
Acta Neuropathol. 2012 Apr;123(4):539-52
pubmed: 22402744
Neurooncol Adv. 2022 Aug 02;4(1):vdac120
pubmed: 36267874
Cancer Cell. 2009 Feb 3;15(2):135-47
pubmed: 19185848
Curr Mol Med. 2015;15(1):82-93
pubmed: 25601471
Cancers (Basel). 2021 Jul 30;13(15):
pubmed: 34359754
Nature. 2022 Sep;609(7929):1021-1028
pubmed: 36131014
Curr Opin Neurobiol. 2001 Feb;11(1):82-8
pubmed: 11179876
Cancer Cell. 2018 Sep 10;34(3):396-410.e8
pubmed: 30205044
Cell Death Dis. 2020 Dec 5;11(12):1035
pubmed: 33279931
Neuro Oncol. 2022 Jul 1;24(7):1178-1190
pubmed: 34935967
Clin Cancer Res. 2013 Nov 15;19(22):6305-12
pubmed: 24077351
Nature. 2016 Feb 4;530(7588):57-62
pubmed: 26814967
Pediatr Blood Cancer. 2013 Mar;60(3):390-5
pubmed: 22887890
Sci Transl Med. 2017 Mar 15;9(381):
pubmed: 28298418
Cancer Cell. 2018 Oct 8;34(4):536-548
pubmed: 30146333
Cells. 2021 Dec 25;11(1):
pubmed: 35011618
Cell Rep. 2015 Jul 28;12(4):599-609
pubmed: 26190112
Clin Cancer Res. 2022 Sep 15;28(18):3950-3957
pubmed: 35833850
Anticancer Res. 2022 Apr;42(4):1697-1706
pubmed: 35346988
Cancer Cell. 2013 Jan 14;23(1):23-34
pubmed: 23291299
PLoS One. 2020 Feb 3;15(2):e0228225
pubmed: 32012186
J Neurosci. 2014 Sep 10;34(37):12527-37
pubmed: 25209290
Science. 2011 Jan 28;331(6016):435-9
pubmed: 21163964
Nature. 2014 Jul 24;511(7510):428-34
pubmed: 25043047
Bioorg Med Chem Lett. 2009 Oct 1;19(19):5576-81
pubmed: 19716296
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Nature. 2019 Aug;572(7767):74-79
pubmed: 31341285
BMC Cancer. 2019 Jun 11;19(1):571
pubmed: 31185958
Int J Mol Sci. 2017 Feb 13;18(2):
pubmed: 28208838
J Hematol Oncol. 2019 Mar 15;12(1):29
pubmed: 30876441
Lancet Oncol. 2018 Jun;19(6):785-798
pubmed: 29753700
Cancer Res. 2002 Mar 15;62(6):1915-9
pubmed: 11912174
Clin Cancer Res. 2014 Feb 15;20(4):912-25
pubmed: 24297863
Nature. 2012 Aug 2;488(7409):106-10
pubmed: 22820256
Acta Neuropathol. 2014 Apr;127(4):593-603
pubmed: 24196163
PLoS One. 2016 Jul 01;11(7):e0154111
pubmed: 27367907
Nature. 2022 Dec;612(7941):787-794
pubmed: 36450980
Bosn J Basic Med Sci. 2018 Feb 20;18(1):8-20
pubmed: 29274272
Nat Commun. 2019 Jan 18;10(1):332
pubmed: 30659187
Cancer Res. 2015 Jan 1;75(1):134-46
pubmed: 25391241
J Clin Oncol. 2015 Aug 20;33(24):2646-54
pubmed: 26169613
JCI Insight. 2019 Jan 10;4(1):
pubmed: 30626740
Pediatr Blood Cancer. 2021 Apr;68(4):e28879
pubmed: 33405376
Mol Cancer Ther. 2019 Jul;18(7):1185-1194
pubmed: 31263027
Cancer Cell. 2016 Apr 11;29(4):508-522
pubmed: 27050100
Cell Death Dis. 2020 Dec 2;11(12):1029
pubmed: 33268769
Oncoscience. 2015 Mar 02;2(4):334-48
pubmed: 26097868
Transl Oncol. 2019 Jan;12(1):96-105
pubmed: 30292066
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Nature. 2010 Dec 23;468(7327):1095-9
pubmed: 21150899
Front Neuroanat. 2011 Apr 21;5:27
pubmed: 21559349
Brain Tumor Pathol. 2019 Jan;36(1):1-6
pubmed: 30523493
Cells. 2022 Jan 23;11(3):
pubmed: 35159191
Pediatr Blood Cancer. 2013 Sep;60(9):1452-7
pubmed: 23554030
Mol Cancer Ther. 2012 Feb;11(2):288-97
pubmed: 22188814
Food Funct. 2015 Nov;6(11):3464-72
pubmed: 26292725
Cancer Res. 2013 Oct 15;73(20):6310-22
pubmed: 24067506
Br J Pharmacol. 2012 May;166(2):447-56
pubmed: 22233238
Nature. 2012 Aug 2;488(7409):49-56
pubmed: 22832581
Cancer Res. 2013 Dec 1;73(23):7068-78
pubmed: 24145352
Neurosurgery. 2015 Feb;76(2):N15-6
pubmed: 25594199
Neuro Oncol. 2013 Jun;15(6):783-7
pubmed: 23460318